NXgenPort (NGP), has designed an innovative and transformative technology to maximize remote care in cancer patients requiring an implantable chemo-port catheter. Combining proven chemo-port efficacy with microchip and sensor technology, NGP measures, monitors and reports physiological body functions in vivo over the course of disease and treatment.
In this episode, Founder and CEO Kathy Skinner shares the details of how this port advances care for a very important patient population and how its quickly gaining momentum.
Clint McGill is addressing one of the biggest challenge in youth sports - building mental toughness. As a former high level baseball player himself,...
Lactiga is a venture-backed, NIH-funded biotherapeutics company developing patented biologics to treat and prevent mucosal infections with a focus on improving the quality of...
Dr. Michael Meighen is a physician who is board certified in Physiatry and Pain Medicine. He is the author of #1 Best Selling Book...
